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Abstract
Background—Although malaria can be prevented with prophylaxis, it is diagnosed in over 100 
Africa-region Peace Corps Volunteers annually. This suggests that prophylaxis non-adherence is a 
problem in these non-immune travelers.
Methods—We investigated Volunteers’ knowledge, attitudes, and practices regarding prophylaxis 
using an internet-based survey during August 19–September 30, 2013. Adherence was defined as 
taking doxycycline or atovaquone-proguanil daily, or taking mefloquine doses no more than 8 days 
apart.
Results—The survey was sent to 3,248 Volunteers. Of 781 whose responses were analyzed, 514 
(73%) reported adherence to prophylaxis. The most common reasons for non-adherence were 
forgetting (n=530, 90%); fear of long-term adverse effects (LTAEs; n=316, 54%); and 
experiencing adverse events that Volunteers attributed to prophylaxis (n=297, 51%). Two hundred 
fourteen (27%) Volunteers reported not worrying about malaria. On multivariate analysis 
controlling for sex and experiencing adverse events Volunteers attributed to prophylaxis, the factor 
most strongly associated with non-adherence was being prescribed mefloquine (OR 5.4, 95% 
confidence interval 3.2–9.0).
Conclusions—We found moderate adherence and a prevailing fear of LTAEs among Volunteers. 
Strategies to improve prophylaxis adherence may include medication reminders, increasing 
education about prophylaxis safety and malaria risk, and promoting prompt management of 
prophylaxis side effects.
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Since 1961, over 215,000 Peace Corps Volunteers (Volunteers) have served worldwide, 46% 
of them in Africa. Most Volunteer deployments last 27 months; as long-term travelers to this 
area, Africa-region Volunteers are at high risk for malaria infection. Peace Corps policy 
requires Volunteers in malaria-endemic countries to take malaria prophylaxis. However, 
malaria is diagnosed in over 100 Africa-region Volunteers each year, suggesting that non-
adherence to prophylaxis is a problem in this population of non-immune travelers.
Concerns about adverse effects of prophylaxis, which are reported by many Volunteers and 
other travelers to malaria-endemic areas, are suspected to play a large role in non-adherence. 
In a cross-sectional study of 2701 Volunteers conducted between 2005 and 2006, 62% of 
respondents reported having a side effect that they attributed to prophylaxis, and 28% 
reported changing prophylaxis as a result [1]. In a 2003 randomized, double-blinded, 
placebo-controlled study of 623 non-immune, short-term travelers to sub-Saharan Africa, 
85% of participants reported a side effect of prophylaxis [2]. It is unclear what proportion of 
symptoms attributed to prophylaxis are truly side effects of the medicine rather than normal 
events related to long-term travel: in a randomized, double-blinded, placebo-controlled study 
of mefloquine versus atovaquone-proguanil in 1013 patients presenting to travel clinics in 
1999, 62% of treatment-emergent adverse effects were determined by the investigators to be 
unrelated to the study drug [3]. Studies of adherence to long-term malaria prophylaxis in 
populations of travelers have shown that adherence is poor overall, and that fear of long-term 
adverse effects (LTAEs), conflicting advice, and complicated or daily dosing strategies are 
common reasons for non-adherence [4,5].
The U.S. Centers for Disease Control (CDC)-recommended options for prophylaxis in 
Africa are mefloquine, doxycycline, and atovaquone-proguanil (Malarone™). From as early 
as 1995 until 2012, Peace Corps policy recommended mefloquine as the drug of choice for 
Volunteers without a history of psychiatric illness serving in Africa region countries. In 
December 2012, in response to concerns on mefloquine safety expressed by some 
Volunteers, and in hopes of increasing overall adherence, the policy was changed to make all 
prophylaxis options equally available. Peace Corps Medical Officers (PCMOs) are 
responsible for Volunteer education pre-deployment about the use and importance of 
uninterrupted prophylaxis, selection of prophylaxis, and management of long-term use of 
prophylaxis for the duration of Volunteers’ service [6]. They are instructed to individualize 
their choice of agent based on area-specific recommendations (e.g., some Volunteers serve in 
regions where CDC does not recommend malaria prophylaxis), drug contraindications and 
precautions, drug tolerance, and dosing schedules. According to Peace Corps policy, 
Volunteers non-adherent to prophylaxis can be terminated from their Peace Corps service. 
Peace Corps has followed this policy.
Between July 7 and September 30, 2013, CDC conducted qualitative and quantitative 
evaluations among active Volunteers with the aim of identifying risk factors for non-
adherence to malaria prophylaxis. We present the findings of the quantitative evaluation.
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In July 2013, we conducted focus-group discussions with convenience samples of 30 active, 
consenting Volunteers in Zambia, a country with high rates of malaria among Volunteers 
(3.9 cases per 100 Volunteer years in 2012[7]), and Senegal, a country with low rates of 
malaria among Volunteers (0.8 cases per 100 Volunteer years in 2012). We also conducted 
interviews with these countries’ PCMOs and each country’s Peace Corps directorship. 
Content of these evaluations centered around participants’ views on and personal experience 
with malaria and malaria prophylaxis, sources for health advice, views on Peace Corps 
administration policies, and Volunteer-PCMO relationships. CDC staff used transcripts of 
these discussions to develop an internet-based survey using SurveyMonkey (SurveyMonkey, 
Palo Alto, CA). A survey was deployed August 19, 2013 by the Peace Corps offices of all 23 
countries with active posts in the Africa region to all active Volunteers in-country. The 
survey was open until September 30, 2013, and completed anonymously by consenting 
Volunteers.
The survey contained questions on currently prescribed malaria prophylaxis and dosing; 
current symptoms attributed to prophylaxis and feared LTAEs (adverse effects occurring 
after Peace Corps as a result of taking prophylaxis during Peace Corps); reasons for taking, 
not taking, or changing prophylaxis; malaria diagnosis, testing, and care history during 
Peace Corps service; knowledge and attitudes related to Peace Corps policies regarding non-
adherence, malaria, and medication in general; country/region of service; use of tobacco and 
recreational drugs, and general demographics. Peace Corps-Headquarters provided 
aggregate, anonymous demographic data on Volunteers in countries where the survey was 
implemented. These data included median age, gender distribution, number of first- and 
second-year Volunteers in each country, and case rates of laboratory-confirmed malaria from 
the year 2012.
Responses were received from Volunteers serving in all countries in the region, including six 
countries where malaria endemicity is non-uniform enough that CDC’s prophylaxis 
recommendations vary within the country: Ethiopia, Kenya, Tanzania, Namibia, Botswana, 
South Africa. Although Peace Corps recommends malaria prophylaxis for all Volunteers 
serving in Ethiopia, Tanzania, and Kenya, Volunteers in all six of these countries may have 
had contact with people who were appropriately counseled not to take prophylaxis. Because 
this might have affected their attitudes toward prophylaxis, we excluded all respondents 
from these six countries.
Descriptive analysis was conducted using SAS 9.3 (SAS Institute, Cary, NC). Adverse 
events were grouped by organ system for portions of the analysis: neuropsychiatric 
symptoms were defined as nightmares/vivid dreams, anxiety, insomnia, dizziness/vertigo, 
depression, limb numbness, psychosis, headache, and tinnitus; gastrointestinal symptoms 
were defined as heartburn, nausea/vomiting, diarrhea, mouth ulcers, constipation, and 
dyspepsia; dermatologic symptoms were defined as sun sensitivity, rash, acne changes, and 
other skin complaints; genitourinary symptoms were defined as yeast infections and urinary 
disturbances; and consistutional symptoms were defined as hair loss, weight changes, and 
fever). For Volunteers prescribed mefloquine, adherence was defined as taking doses of the 
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medication no more than eight days apart. For those prescribed atovaquone-proguanil or 
doxycycline, adherence was defined as taking the medication once a day at any time of day. 
Odds ratios were calculated for all major factors assessed in the survey. Factors significant 
on crude analysis were further analyzed using multivariate logistic regression to identify 
predictors of non-adherence.
3. Results
3.1 Geography and demographics
An email describing and linking to an online Volunteer survey was sent to 3,248 Volunteers 
across 23 countries in the Africa region, 2,307 of them serving in countries with uniform 
prophylaxis recommendations. We received 1,184 unique, valid responses to the survey 
between August 19th and September 30th, 2013. After excluding 193 respondents who did 
not identify the country in which they were serving and 210 from countries with non-
uniform prophylaxis recommendations, survey data from 781 respondents remained, 
yielding a response rate of 34%. Volunteers from countries with uniform recommendations 
were more likely to be <26 years old than those from countries with non-uniform 
recommendations (59% vs. 45%, X2=12.6, p<0.001), and were more likely to have served 
>1 year in Peace Corps (61% vs. 31%, X2=92.1, p<0.001); there were no statistically 
significant differences in sex between the groups.
To determine whether geographic differences in malaria incidence among Volunteers were 
associated with differences in response rates, we compared country response rates with 
malaria case rates reported by each country’s PCMO team. There was no correlation 
between response rates and case rates (Spearman rho −0.13, p = 0.0.67; Table 1).
To determine the representativeness of the Volunteers included in the study compared to 
survey invitees, we compared median age, proportion female, and years of service between 
the two groups. The median age group of included Volunteers was 22–25 years, comparable 
to 25 years among invitees. Five hundred twenty-six (68%) included Volunteers were 
female, compared to 2069 (64%) invitees (p=0.028), and 307 (39%) were in their first year 
of service, compared to 1515 (47%) invitees (p<0.001).
3.2 Adherence to prophylaxis
Three hundred eighty Volunteers (49%) reported being prescribed mefloquine, 304 (39%) 
doxycycline, and 97 (12%) atovaquone-proguanil. Two hundred seventy-six (35%) 
respondents reported having changed prophylaxis at some point during their service.
Of 703 respondents reporting how often they take their prescribed prophylaxis, 514 (73%) 
reported taking it in adherence with their prescribed dosing regimen. Adherence was 90% 
among those prescribed atovaquone-proguanil (n=77), 84% (n=231) among those prescribed 
mefloquine, and 60% (n=206) among those prescribed doxycycline.
Thirty-eight (5%) and 29 (4%) respondents reported taking prophylaxis only seasonally and 
only when traveling away from their posts, respectively, and 335 (72%) females and 174 
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(75%) males reported adherence. Among all age groups, adherence was lowest in 
respondents aged 22–25 years.
3.3 Reasons for non-adherence
The most commonly cited reason for adherence to prophylaxis was the perception that the 
prophylaxis prescribed was effective at preventing malaria (n=747, 98%). The most common 
reasons for non-adherence were forgetting to take prophylaxis (n=530, 90%), fear of long-
term adverse events (n=316, 54%), and having experienced adverse effects they attributed to 
prophylaxis (n=297, 51%). Other reasons for adherence and non-adherence are listed in 
Table 2.
Among those who reported forgetting as a reason for non-adherence, the most commonly 
reported setting was travel or another disruption in routine (n=266, 49%). Among those who 
forgot prophylaxis while traveling, not bringing prophylaxis (n=232, 87%) was more 
common than bringing prophylaxis and forgetting to take it (n=39, 15%).
Two hundred seventy-six (38%) of 724 Volunteers acknowledged fear of having LTAEs after 
their Peace Corps service. The LTAEs most commonly feared were neuropsychiatric 
problems (n=155, 56%), unspecified problems (n=101, 37%), cancer (n=32, 12%), and sun 
sensitivity (n=31, 11%). Twenty-seven (10%) Volunteers were concerned about liver 
problems as an LTAE of prophylaxis.
Of 733 Volunteers, 359 (49%) experienced adverse events during Peace Corps service that 
they attributed to prophylaxis: 219 (61%) were prescribed mefloquine, 133 (37%) were 
prescribed doxycycline, and 7 (2%) were prescribed atovaquone-proguanil. Of all 380 
patients prescribed mefloquine, 215 (57%) attributed a neuropsychiatric event to the drug, 
most commonly nightmares/vivid dreams, anxiety, and insomnia. Adverse events most 
commonly reported by those prescribed doxycycline were sun sensitivity, nausea/vomiting, 
and heartburn, and those most commonly reported by those prescribed atovaquone-proguanil 
were nausea/vomiting, nightmares/vivid dreams, and insomnia (Table 3, column percents).
Among all Volunteers experiencing any adverse event they attributed to prophylaxis, 
neuropsychiatric events were reported by 242 (67%), while 118 (33%) reported 
gastrointestinal events, 102 (28%) reported dermatologic events, 66 (18%) reported 
constitutional events, and 37 (10%) reported genitourinary events. Among neuropsychiatric 
adverse events reported, nightmares/vivid dreams, anxiety, and insomnia were most 
common. All adverse events attributed to prophylaxis irrespective of respondent adherence 
are listed in Table 3.
Among Volunteers who did not experience adverse events that they attributed to their 
prophylaxis, adherence to atovaquone-proguanil was 91% (n=72), adherence to doxycycline 
was 90% (n=128), and adherence to mefloquine was 74% (n=94).
3.4 Malaria knowledge, history, and health behaviors
Of Volunteers answering questions on their knowledge about morbidity/mortality risks 
related to malaria, 758 (99%) correctly indicated that it was possible to die from malaria and 
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636 (97%) correctly indicated that it is possible to get permanent disability from malaria. 
Only 61 (10%) indicated that it was highly likely a person would die if they became infected 
with malaria, and 74 (12%) indicated that it was possible to become immune to malaria by 
being infected with malaria.
Two hundred fourteen (27%) Volunteers indicated they were not worried about malaria, 
most often because they believed malaria can be treated quickly (n=181, 85%). Other 
common reasons were knowing non-host country nationals (HCN; n=93, 44%) or HCN 
(n=71, 33%) who had survived malaria, the belief that malaria is treatable and not a serious 
disease (n=4, 20%), and having personally survived malaria (n=48, 22%).
Seventy-nine (10%) Volunteers reported having been diagnosed with malaria during their 
Peace Corps service, and 332 (43%) acknowledged having had at least one malaria test 
during their service. Although 119 (15%) Volunteers had been tested for malaria by their 
PCMO, 201 (26%) had been tested for malaria elsewhere, and 69 (9%) had been tested for 
malaria with a rapid diagnostic test (RDT) not supplied by Peace Corps. Thirty-three (4%) 
Volunteers had taken an antimalarial drug not prescribed by Peace Corps.
When asked whom they would contact first when ill, 461 (59%) Volunteers answered, “a 
PCMO.” Two hundred twenty-five (29%) Volunteers acknowledged having called their 
PCMO with malaria symptoms, while 114 (15%) Volunteers acknowledged having had 
malaria symptoms without calling the PCMO. Nine (1%) Volunteers acknowledged having 
lied to the PCMO about an RDT result for any reason. Nineteen (2%) Volunteers reported 
using recreational drugs at least once a week. Six hundred ninety-eight (91%) Volunteers 
answering questions about chronic medications indicated they either were taking long-term 
medications or would take long-term medications, or that it could be appropriate to take a 
medication for disease prevention.
3.5 Bivariate and multivariate analysis
Factors significantly associated with non-adherence on bivariate analysis are listed in Table 
4. For the purpose of multivariable modeling, we excluded Volunteers prescribed malarone 
due to the relatively small number in this group. Treatment-seeking behavior, such as 
seeking diagnosis outside of PCMO care or self-treating with non-PC drugs, were not 
associated with nonadherence. In a model controlling for sex and experiencing adverse 
events that they attributed to prophylaxis, factors significantly associated with higher odds of 
non-adherence were being prescribed mefloquine (OR 5.4, 95% confidence interval [CI] 
3.2–9.0), not being worried about malaria (OR 2.6, 95% CI 1.6–4.1), having been in Peace 
Corps service >1 year (OR 1.8, 95% CI 1.2–2.8), and being <26 years old (OR 1.7, 95% CI 
1.1–2.6; Table 4).
4. Discussion
The most common reason Volunteers gave for non-adherence was simply forgetting, 
suggesting a role for reminder interventions. These may include strategies for self-managing 
medication or automated reminders, and could potentially include an SMS reminder system 
similar to those used throughout rural Africa for antiretroviral therapy [8].
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Fear of long-term adverse effects was another important reason for non-adherence. The top 
adverse effect feared by Volunteers was “unspecified problems,” and the next five most 
commonly feared symptoms were neuropsychiatric. When these five symptoms were cited 
as feared LTAEs, over 80% of the time it was by Volunteers prescribed mefloquine. 
Although mefloquine is known to cause neuropsychiatric effects in 10–15% of people while 
it is being taken [9,10], published data demonstrating mefloquine side effects presenting or 
persisting after discontinuation of the medication are limited to several case reports of 
ototoxicity [11]. Serious adverse events due to mefloquine are rare [12]. On July 29, 2013, 
the Food and Drug Administration (FDA) added a black-box warning to mefloquine 
labeling, advising providers and patients about the reports of long term ototoxicity.
About half of the Volunteers in our study attributed adverse events to their malaria 
prophylaxis, and the drug with the largest proportion of adverse events attributed was 
mefloquine (59%). In other studies, mefloquine adverse effects have been reported by 62% 
[1] and 67% [3] of adult subjects taking the drug. The three most commonly drug-attributed 
adverse events in our cohort were neuropsychiatric, and were also most commonly reported 
by Volunteers prescribed mefloquine. Neuropsychiatric events have been previously 
associated with mefloquine: in a randomized, double-blind trial comparing mefloquine to 
atovaquone-proguanil, 29% of subjects taking mefloquine had any neuropsychiatric event 
[3]. In that trial, 14% of those taking atovaquone-proguanil also reported neuropsychiatric 
events. Because atovaquone-proguanil is not considered to be a cause of neuropsychiatric 
side effects, these findings suggest that overattribution of adverse events to medications may 
be a concern in antimalarial drug safety studies.
Compared to that trial, a higher proportion of our respondents (56%) reported 
neuropsychiatric events, especially vivid dreams, anxiety, and depression. Several reasons 
may exist for this. First, Volunteers experiencing adverse events attributed to prophylaxis or 
with heightened concern for LTAEs may have been more motivated to respond to the survey, 
resulting in skewed measures of association. Second, substantial overlap exists between 
mefloquine side effects and symptoms associated with the stressors innate to Peace Corps 
service. Although these symptoms may be physiologic, Volunteers may identify them as a 
side effect of prophylaxis. Finally, many Volunteers are aware of mefloquine’s side effects 
due to increased publicity via the popular press, blogs, and social media. For example, 
although the FDA black box warning for mefloquine was issued only a month before the 
survey, several Volunteers were aware of the warning. The availability of Internet-based 
information sources among Volunteers compared to that among participants in other studies 
may be higher. Frequent recreational drug use was acknowledged by only 2% of 
respondents. Although this behavior may have been underreported, it seems unlikely to be a 
contributor to increased reporting of neuropsychiatric symptoms. Negative perceptions of 
mefloquine related to these sources may explain our finding that being prescribed 
mefloquine was the single factor most strongly associated with non-adherence on 
multivariable analysis, even when controlling for experienced adverse events attributed to 
prophylaxis. Under Peace Corps’ new policy allowing Volunteers equal access to all 
prophylaxis options, it may be easier for Volunteers who prefer a non-mefloquine option to 
change medications. Meanwhile, Volunteers who prefer the medication due to its weekly 
administration or for other reasons will be able to continue using it.
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Atovaquone-proguanil is a daily medication with few side effects [3,13], and few Volunteers 
experienced adverse events they attributed to it. Although this is a safe medication for many, 
its dosing and cost should be considered.
Of note, among reasons for non-adherence, Volunteers ranked concern for interaction with 
alcohol and other medications (including oral contraceptives) relatively low. No evidence 
exists to support the interaction of mefloquine, doxycycline, or atovaquone-proguanil with 
alcohol or oral contraceptives.
Almost all Volunteers knew that death and disability were possible consequences of malaria 
infection. However, 27% of Volunteers acknowledged not being worried about malaria, and 
this perception was associated with increased odds of prophylaxis non-adherence. When 
detected and treated early, malaria often has limited morbidity and mortality. However, the 
risk of progression to severe illness is not completely eliminated by early treatment, and in 
remote areas, obtaining comprehensive early care for malaria may be difficult. Volunteers 
must be educated on these risks, emphasizing that prevention is essential.
The practice of attributing even low-grade symptoms to malaria in their communities may 
lead to the perception that malaria is not something to be concerned about. Volunteers 
should be aware of malaria prevalence in their communities, and of the importance of 
obtaining the best-available healthcare, including proper diagnosis and treatment for malaria 
symptoms.
Twelve percent of Volunteers indicated that they thought it was possible to become immune 
to malaria by being infected. Most Peace Corps tours are unlikely to include sufficient 
malaria exposure to induce any meaningful immunity, and there is no laboratory test to 
measure partial immunity. The perception that repeated infections reduce risk can lead to 
riskier behavior, including non-adherence to prophylaxis.
The only health seeking behavior associated with nonadherence on crude analysis was not 
calling a PCMO when having malaria symptoms, reported by 15% of Volunteers and more 
common among non-adherent Volunteers. This practice can lead to delays in recognizing 
and treating malaria, further increasing the risk of progression to severe illness or death. 
Self-treatment of malaria was not associated with non-adherence, suggesting that non-
adherers do not seem to be relying on self-treatment in place of prophylaxis. However, 4% 
of Volunteers acknowledged self-treatment with drugs not provided by Peace Corps—a 
concerning finding, given the high prevalence of counterfeit antimalarial drugs in sub-
Saharan Africa [14]. Volunteers should be educated about the risks of self-treatment.
In our study, 73% of Volunteers reported adherence to antimalarial drugs; a relatively high 
proportion when compared to other studies of malaria prophylaxis in long term travelers 
with observed adherence between 59–62% of participants [5,15,16]). Volunteers younger 
than 26 years and with more than 1 year of Peace Corps experience had increased odds of 
non-adherence to prophylaxis. This may be explained by a greater sense of invulnerability in 
this population, and similar findings have been documented elsewhere: in a study of 
humanitarian workers, nonadherence to malaria prophylaxis increased in a linear fashion 
with the duration of mission, and was 81% in workers who had served in missions lasting 12 
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to 18 months [17]. Interventions to improve adherence in more experienced Volunteers could 
include education both at the start of service and as a refresher course mid-service, with a 
focus on malaria morbidity and mortality and the important benefits of preventive 
medication.
Some strengths of this study included its relatively rapid execution, its dissemination to all 
Africa-region Volunteers, and its ability to measure multiple beliefs and behaviors. However, 
there were several important limitations to this study. First, the response rate among PCVs 
was only 34%, and non-response bias might have affected the results.. Volunteers who were 
non-adherent might have been less likely to participate, just as those who were adherent may 
have been more likely to participate, possibly resulting in the higher than expected 
proportion of respondents adherent to prophylaxis. Second, because the study relied on 
Internet access for survey completion, selection bias might have occurred (e.g. selecting for 
Volunteers posted to more urban areas or those with Internet-enabled devices). Because 
older Volunteers are more likely to be assigned to urban, well-resourced areas, this may have 
resulted in relatively reduced input from younger Volunteers. Third, because Volunteers 
knew adherence was expected from them, social desirability bias might have occurred. 
Finally, the exclusion of Volunteers from countries with geographically non-uniform 
prophylaxis recommendations might have selected for Volunteers exposed to fewer 
conflicting recommendations, resulting in participation of a non-representative population.
Although it is possible that Volunteers who feel more personally threatened by malaria may 
have been more likely to complete our survey, there was no statistically significant 
correlation between 2012 malaria case rates and response rate to our survey. It is unlikely 
there was a relationship between malaria incidence among a country’s Volunteers and their 
likelihood of responding to our survey.
On the basis of our findings, we have presented several strategies to improve malaria 
prophylaxis adherence in Peace Corps Volunteers and other long-term travelers to malaria-
endemic countries, among them education that targets common fears and rumors about 
prophylaxis drugs, and automated or other reminder systems. The training curriculum 
delivered by PCMOs to Volunteers has already been updated and standardized, and Peace 
Corps is initiating evaluation studies to assess the impact of training (Barry G. Simon, MD, 
Peace Corps Medical Director; personal communication; August 2013). Given the 
importance of feared LTAEs in motivating non-adherence, there is a need for further study 
on this subject.
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Table 1







(cases/100 Volunteers)Country N (%)
Togo 29 (3.7) 13.1
Sierra Leone 49 (6.3) 7.9
Uganda 61 (7.8) 7.6
Liberia 44 (5.6) 5.2
Malawi 16 (2.0) 4.6
Cameroon 89 (11.4) 4.6
Benin 80 (10.2) 4.1
Burkina Faso 15 (1.9) 4.1
Zambia 47 (6.0) 3.9
Mozambique 35 (4.5) 3.6
Ghana 84 (10.8) 3.5
Rwanda 42 (5.4) 1.5
The Gambia 34 (4.4) 1.2
Senegal 26 (3.3) 0.8
The Gambia 25 (3.2) 0
Madagascar 87 (11.1) 0
Swaziland 18 (2.3) 0
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Landman et al. Page 14
Table 4
Factors associated with non-adherence.
Bivariate analysis Multivariate analysis
Unadjusted ORa (95% CIb) Adjusted OR (95% CI)
Mefloquine prescribed 3.5 2.4–5.1 5.4 3.2–9.0
Not worried about malaria 3.3 2.2–4.8 2.6 1.6–4.1
>1 years of Peace Corps service 1.8 1.2–2.5 1.8 1.2–2.8
Age <26 years 1.8 1.2–2.6 1.7 1.1–2.6
Attribute adverse events to prophylaxis 1.9 1.2–2.8 1.5 0.9–2.3
Sex female 1.2 0.8–1.8 1.0 0.6–1.6
Had malaria symptoms during Peace Corps
but did not call the PCMOc
2.1 1.3–3.3 - -
Diagnosed with malaria during Peace Corpsc 1.9 1.1–3.3 - -
Fear LTAEsc 1.6 1.1–2.4 - -
Would take long-term medications for
preventive purposesc
0.5 0.3–0.9 - -
Feel is it likely to die from malaria infectionc 0.3 0.1–0.8 - -
aOR=Odds ratio
bCI=confidence interval
cNot included in final multivariable model
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